Loading
Virus-based Gene Therapy Research / CRISPR and Genetic Engineering · Journal article
Med · July 22, 2026
A consensus or society position rather than new primary data.
This is a published ethical framework proposing that heritable genome editing should be permissible for catastrophic monogenic disorders under stringent safeguards, but prohibited for polygenic risk reduction and enhancement due to insufficient evidence and significant social risks. The authors argue that governance should be evidence-based and risk-proportionate, not categorical.
Journal article. Future persons who might receive heritable genome editing; specifically applied to monogenic, polygenic, and enhancement contexts.
For catastrophic monogenic disorders in which preimplantation selection cannot yield unaffected embryos, heritable editing is permissible and may be required by beneficence For polygenic interventions, current scientific uncertainty makes clinical application premature due to insufficient predictive validity and poorly understood pleiotropic effects For enhancement, benefits are positional, risks of social stratification are significant, and evidence base is absent
No empirical data on safety, efficacy, or long-term outcomes of heritable genome editing in humans No quantified risk estimates or comparative harms analysis provided
This framework suggests clinicians and policymakers should distinguish between heritable interventions by indication and evidence base: permitting catastrophic monogenic applications under safeguards while restricting polygenic and enhancement uses. Professionals should recognize that blanket prohibition may itself be ethically problematic where evidence supports intervention.
This is a normative ethical framework and expert consensus statement that proposes governance principles for heritable gene therapy, not an empirical study of clinical outcomes or safety.
This framework suggests clinicians and policymakers should distinguish between heritable interventions by indication and evidence base: permitting catastrophic monogenic applications under safeguards while restricting polygenic and enhancement uses. Professionals should recognize that blanket prohibition may itself be ethically problematic where evidence supports intervention.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
CRISPR-Cas systems, base editing, and prime editing have made precise genetic interventions possible, and several approved therapies now treat monogenic disorders that were previously untreatable. Heritable genome editing remains ethically contested. We argue that heritable interventions should not be treated as a single category subject to uniform prohibition. We distinguish three targets: catastrophic monogenic disorders, polygenic risk reduction, and non-disease trait enhancement. For catastrophic monogenic conditions in which preimplantation selection cannot yield unaffected embryos, heritable editing is permissible, and the duty of beneficence toward future persons may require it. When the alternative is certain severe suffering or early death, the expected benefits clearly outweigh the risks. For polygenic interventions, current scientific uncertainty makes clinical application premature: predictive validity remains insufficient and pleiotropic effects are poorly understood. For enhancement, the case is weaker still. Some of its benefits are positional; the risks of social stratification are significant; and the evidence base is absent. We conclude that governance frameworks should permit what the evidence supports under stringent safeguards and prohibit what it does not. The central ethical questions concern welfare, not appeals to nature or abstract notions of dignity. Where the evidence warrants it, failing to pursue heritable gene therapy responsibly may itself be an ethical failure. We outline a translational pathway for ethical germline gene editing.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.